5 recruiting, 3 completed, 3 not yet recruiting, 1 terminated. 13 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Recruiting 5, Completed 3, Not yet recruiting 3, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Recruiting 3 |
Follow Multiple Sclerosis (MS): new trials by email Literature Review of Multiple Sclerosis (MS) trials Research Report on Multiple Sclerosis (MS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis. Universal STAR-T Cell Injection - Multiple Sclerosis (MS) | Phase 1 | Not yet recruiting | Daishi Tian | 24 | 2026-04-07 | 2026-04-13 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 1 | Not yet recruiting | Huashan Hospital | 15 | 2026-02-01 | 2026-01-15 |
| A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases LCAR-AIO T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD) | Phase 1 | Withdrawn | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-06-17 | 2026-06-24 | |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM) | Phase 1 | Recruiting | RenJi Hospital | 30 | 2024-03-20 | 2025-07-25 |
| Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy Clemastine Fumarate, Placebo - Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 74 | 2023-08-01 | 2026-07-02 |
| Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers 18F-OP-801 - Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD) | Phase 1 / Phase 2 | Recruiting | Ashvattha Therapeutics, Inc. | 65 | 2023-02-02 | 2025-05-02 |
| A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis 11C-BMS-986196 - Multiple Sclerosis (MS) | Phase 1 | Terminated | Bristol-Myers Squibb | 10 | 2021-12-10 | 2025-04-24 |
| Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis ANK-700, Placebo - Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Anokion SA | 34 | 2020-11-06 | 2025-05-31 |
| A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis Metformin, Placebo - Multiple Sclerosis (MS) | Phase 1 / Phase 2 | Recruiting | The Hospital for Sick Children | 20 | 2020-02-24 | 2025-09-23 |
| A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis Ocrelizumab, rHuPH20 - Multiple Sclerosis (MS) | Phase 1 | Completed | Hoffmann-La Roche | 134 | 2019-08-12 | 2025-07-08 |
| Avonex®: Safety, Blood Levels and Effects Interferon beta 1a, (IM) AVONEX® - Multiple Sclerosis (MS) | Phase 1 | Completed | Trio Medicines Ltd. | 77 | 2001-01-01 | 2013-05-27 |
Multiple Sclerosis (13) · Myasthenia Gravis (4) · Neuromyelitis Optica (4) · Autoimmune Diseases of the Nervous System (2) · Lupus Erythematosus, Systemic (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Scleroderma, Systemic (2) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Myositis (1) · Parkinson Disease (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Recurrence (1) · Respiratory Aspiration (1)
Autoimmune Diseases (13) · Demyelinating Autoimmune Diseases, CNS (13) · Demyelinating Diseases (13) · Immune System Diseases (13) · Nervous System Diseases (13) · Autoimmune Diseases of the Nervous System (11) · Neuromuscular Diseases (6) · Neurodegenerative Diseases (5) · Cranial Nerve Diseases (4) · Eye Diseases (4) · Myelitis, Transverse (4) · Neoplasms (4) · Neoplasms by Site (4) · Nervous System Neoplasms (4) · Neuromuscular Junction Diseases (4)
Clemastine (1) · Cyclophosphamide (1) · Interferon beta-1a (1) · Metformin (1) · Sugars (1) · fludarabine (1) · ocrelizumab (1)
Anokion SA (1) · Ashvattha Therapeutics, Inc. (1) · Bristol-Myers Squibb (1) · Daishi Tian (1) · Hoffmann-La Roche (1) · Huashan Hospital (1) · RenJi Hospital (1) · The Affiliated Hospital of Qingdao University (1) · The Hospital for Sick Children (1) · Tongji Hospital (1) · Trio Medicines Ltd. (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University of California, San Francisco (1)
China (5) · United States (5) · United Kingdom (2) · Canada (1)
Ari J Green, MD, MCR (1) · Chuan Qin (1) · Daishi Tian (1) · E. Ann Yeh, MA, MD, FRCPC, Dip ABPN (1) · Farshad Moradi, MD (1) · Nan Shen, MD & PhD (1) · Steve Warrington (1)